Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa.

Tropical Medicine & International Health : TM & IH
Charlotte MuhekiKaren I Barnes

Abstract

There is growing international evidence that artemisinin-based combination therapy (ACT) is one of the few effective measures available to 'Roll Back Malaria'. However, concerns about the costs and affordability of ACT are obstacles to its widespread implementation. This paper explores some economic aspects of the implementation of artemether-lumefantrine (AL) to replace sulphadoxine-pyrimethamine (SP) in the KwaZulu Natal (KZN) province, South Africa. Recurrent and capital costs for malaria treatment were compared at baseline and post-intervention for nine clinics and a sentinel rural district hospital. Changes in the unit costs of, and total expenditure on, malaria services were calculated and the cost effectiveness of AL relative to SP was assessed. The number of outpatient malaria cases and inpatient admissions both declined by 94% between 2000 and 2002. After accounting for the role of concurrent improvements in vector control, it was conservatively estimated that 36% of the decline in outpatient cases and 46% for inpatient admissions was attributable to changing the first-line drug to AL. Although AL is considerably more expensive than SP, its improved cure rate and reduced malaria transmission resulted in an estimated 20...Continue Reading

References

Oct 14, 1998·Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie·J F TrapeF Simondon
Jun 29, 2000·Medical and Veterinary Entomology·K HargreavesM Coetzee
Jan 5, 2002·Trends in Parasitology·R W SnowK Marsh
Oct 16, 2002·Trends in Parasitology·Nicholas J White
Jan 16, 2004·Lancet·M AdjuikUNKNOWN International Artemisinin Study Group

❮ Previous
Next ❯

Citations

Jul 31, 2007·Transactions of the Royal Society of Tropical Medicine and Hygiene·H Y MyintN J White
Jul 21, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Piero Olliaro
Oct 1, 2005·BMJ : British Medical Journal·Grace MalengaChristopher J M Whitty
Jul 20, 2012·PharmacoEconomics·Paul GavazaStar Khoza
Oct 19, 2005·Emerging Infectious Diseases·G Dennis ShanksRobert W Snow
Nov 13, 2013·The American Journal of Tropical Medicine and Hygiene·Alison B ComfortPhilip E Thuma
Feb 27, 2010·European Journal of Clinical Pharmacology·Sakina Babikir ElaminTarig Abedelgadir Mohamad
Mar 8, 2011·Bulletin of the World Health Organization·Wendy A DavisTimothy M E Davis
Sep 1, 2009·Expert Review of Clinical Pharmacology·Kesara Na-Bangchang
Sep 2, 2008·Travel Medicine and Infectious Disease·S DubeA A Hoosen
Mar 24, 2006·Tropical Medicine & International Health : TM & IH·D ZurovacR W Snow
Jun 21, 2005·Lancet·Omar Aftab, Fahd Khalid Syed
Dec 14, 2006·Expert Opinion on Pharmacotherapy·Gilbert KokwaroAlexis Nzila
Dec 9, 2016·The American Journal of Tropical Medicine and Hygiene·Valentine DuruDidier Ménard
Nov 1, 2005·Current Opinion in Infectious Diseases·Elizabeth A Ashley, Nicholas J White

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.